
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Department of Environmental and Biomolecular Systems, Oregon Graduate Institute School of Science and Engineering; 2 OHSU Cancer Institute; and 3 Department of Public Health and Preventive Medicine, Oregon Health and Science University, Portland, Oregon
Requests for reprints: James F. Pankow, Department of Environmental and Biomolecular Systems, Oregon Graduate Institute School of Science and Engineering, Oregon Health and Science University, 20000 NW Walker Road, Beaverton, OR 97006-8921. Phone: 503-748-1070; Fax: 503-748-1464. E-mail: pankow{at}ebs.ogi.edu
Toxicant deliveries (by machine smoking) are compiled and associated cancer risks are calculated for 13 carcinogens from 26 brands of conventional cigarettes categorized as "regular" (R), "light" (Lt), or "ultralight" (ULt), and for a reference cigarette. Eight "potentially reduced exposure product" (PREP) cigarettes are also considered. Because agency-to-agency differences exist in the cancer slope factor (CSF) values adopted for some carcinogens, two CSF sets were used in the calculations: set I [U.S. Environmental Protection Agency (EPA)accepted values plus California EPAaccepted values as needed to fill data gaps] and set II (vice versa). The potential effects of human smoking patterns on cigarette deliveries are considered. Acetaldehyde, 1,3-butadiene, and acrylonitrile are associated with the largest calculated cancer risks for all 26 brands of conventional cigarettes. The calculated risks are proportional to the smoking dose z (pack-years). Using CSF set I and z = 1 pack-year (7,300 cigarettes), the calculated brand-average incremental lifetime cancer risk
values are R, 6 x 105; Lt, 5 x 105; and ULt, 3 x 105 (cf. typical U.S. EPA risk benchmark of 106). These values are similar, especially given the tendency of smokers to "compensate" when smoking Lt and ULt cigarettes.
is the brand-average per pack-year subtotal risk for the measured human lung carcinogens. Using CSF set I, the
values for R, Lt, and ULt cigarettes account for
2% of epidemiologically observed values of the all-smoker population average per pack-year risk of lung cancer from conventional cigarettes. RPREP (%) is a science-based estimate of the possible reduction in lung cancer risk provided by a particular PREP as compared with conventional cigarettes. Using CSF set I, all RPREP values are <2%. The current inability to account for the observed health risks of smoking based on existing data indicates that current expressed/implied marketing promises of reduced harm from PREPs are unverified: there is little reason to be confident that total removal of the currently measured human lung carcinogens would reduce the incidence of lung cancer among smokers by any noticeable amount. (Cancer Epidemiol Biomarkers Prev 2007;16(3):58492)
This article has been cited by other articles:
![]() |
S. Lin, V. Tran, and P. Talbot Comparison of toxicity of smoke from traditional and harm-reduction cigarettes using mouse embryonic stem cells as a novel model for preimplantation development Hum. Reprod., February 1, 2009; 24(2): 386 - 397. [Abstract] [Full Text] [PDF] |
||||
![]() |
G M Paszkiewicz and J L Pauly Spectrofluorometric method for measuring tobacco smoke particulate matter on cigarette filters and Cambridge pads Tob. Control, September 1, 2008; 17(Suppl_1): i53 - i58. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Givel FDA legislation Tob. Control, August 1, 2007; 16(4): 217 - 218. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |